🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🆕 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline highlights the importance of the most recent clinical evidence in treating patients w/ heart attacks and other #cvACS. Access the guideline here: bit.ly/41md07V JACC Journals #ClinicalGuidelines #JACC

2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Insertion of a microaxial flow pump (Impella) to prevent death in in cardiogenic shock has received a class IIa LOE B-R recommendation. IABP and VA-ECMO are class III for rourine use.

The definition of a high-risk plaque should be expanded beyond the traditional focus on plaque rupture and thin-cap fibroatheroma in the setting of #cvACS. 🔎 🆕 #JACCIMG Position Statement: bit.ly/3QGXmPi JACC Journals

🔴Use of DOACs in patients with atrial fibrillation on chronic hemodialysis ⤵️ #2024Review #openAccess 🔹sciencedirect.com/science/articl… #CardioEd #MedEd #cardiotwitter #cardiology #medtwitter #medical #MedTwitter #MedX #meded #cardiox #cardioed #CardioTwitter #CVD #medicine

🔴Anticoagulation comparison chart 🔹Apixaban, Rivaroxaban, dabigatran, and warfarin ! Looking for a quick & convenient way to compare different #DOACs & #warfarin?! Look no further than NATF's #anticoagulation comparison chart! See the full chart at hubs.la/Q01vTd1y0

💙Top🔟Trials del 2024 en Enfermedad Coronaria Crónica🪸 según #EHJ: ·  Nueva nomenclatura para isquemia miocárdica: Se propone redenominar en síndromes miocárdicos isquémicos y clasificarlos como "agudos y no agudos". 📄academic.oup.com/eurheartj/adva… #IHD #CCS #CVD #CCD #CCTA #CABG

Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis just published in #EHJ 👉 ow.ly/TjHp50VeAzF Rocco Montone EHJ Editor-in-Chief #heartfailure

The year in cardiovascular medicine 2024: the top 10 papers in thrombosis and antithrombotic treatment. Read more in #EHJ! European Society of Cardiology European Society of Cardiology Journals #thrombosis academic.oup.com/eurheartj/adva…

Oral Ozempic reduced major adverse cardiovascular events in a large randomized trial of 9,650 participants with T2 diabetes and high-risk NEJM #ACC25 nejm.org/doi/full/10.10…

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms,

And here are finally the 5-year results of Evolut Low Risk, a trial in which the self-expanding prosthesis holds its own against surgery. A trial where, let’s remember, the average age was 74 years. For years, to the question: 'How long does a TAVI prosthesis last?' we didn’t

#ACC25 Day 2, here is the summary of today’s trials (I haven’t included the follow-up extensions of Evolut Low Risk, Triluminate, and FAME 3). Today, I counted at least 2 NEJM, 4 Lancet, 1 Nature, 1 JAMA, 1 Circulation, and 1 JACC. 1. MIGHTy-Heart = In-home paramedic visits for

Relevant calcified coronary artery disease may be present in ~20% of patients undergoing PCI, and it is known to add procedural challenges and risks. This State-of-the-Art review aims to present the contemporary clinical approach and procedural planning for patients with

TAVI outperforms surgery in women with severe aortic stenosis. A game-changer in structural heart disease. Read more in EHJ. doi.org/10.1093/eurhea… #TAVI #aorticvalve #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

M m M kl mlmnz

Efficacy of Colchicine in Reducing Major Adverse Cardiovascular Events: a Meta-Analysis of Randomized Controlled Trials! academic.oup.com/eurheartj/adva… #EHJ #cardiotwitter #colchicine #ischaemia #stroke @ESC_journals European Society of Cardiology

🔴Association Between Coronary Artery Spasm and Atherosclerotic Disease ⤵️ State of the Art #2025Review #openaccess JACC Journals 🔹jacc.org/doi/10.1016/j.…

.Presentación de Tenecteplase en Argentina. Fibrinolitico de facil administración en bolo rápido. Va a cambiar la historia del infarto en nuestro país acortando los tiempos a la reperfusión y salvando vidas Boehringer Ingelheim Gerardo Zapata, MD, MTFAC Alfonsina Candiello Sociedad Argentina de Cardiología FAC

infobae.com/salud/2025/05/… Fundación Favaloro 🫀 Sociedad Argentina de Cardiología FAC

.Nice session at FAC congress in Mendoza, Argentina. Wonderful lecture Dr Roxana Mehran. Hope to see soon al Favaloro Cardiovasvular Symposium in September Sociedad Argentina de Cardiología Fundación Favaloro 🫀